Navigation Links
WuXi PharmaTech Announces Second Quarter 2007 Results
Date:9/5/2007

oking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among the factors that could cause WuXi PharmaTech's actual results to differ from what the Company currently anticipates may include the Company's limited operating history; its reliance on a limited number of customers to continue to account for a high percentage of its revenues; risk of payment failure by any of its large customers, which could significantly harm the Company's cash flows and profitability; dependency upon the continued service of our senior management and key scientific personnel and ability to retain our existing customers or expand our customer base. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our prospectus filed with the Securities and Exchange Commission on August 9, 2007, and is available on the Securities and Exchange Commission's website at http://www.sec.gov . For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 11 of our prospectus. Our actual results of operations for the second quarter of 2007 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, WuXi PharmaTech undertakes no obligation to update or revise these forward-looking sta
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  Caris Life Sciences ® , a leading ... precision medicine, today announced the presentation of data ... of Caris Molecular Intelligence ® , the company,s ... identify targeted treatment options for patients with rare ... results of which are to be presented in ...
(Date:5/29/2015)... RESEARCH TRIANGLE PARK, N.C. , May 29, 2015 ... today that Roger Jeffs , Ph.D., President and Co-Chief ... update on the company,s business at the Jefferies 2015 Global ... The presentation and the immediately following Q&A session ... AM Eastern Time, and can be accessed via a live ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Seoul ... leader in LED technology, on May 28th announced ... market share by strengthening its high efficient and ... application , Since 2011 Seoul Semiconductor has developed ... lighting market and has supplied LEDs for headlamps ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ... and Companies"  to their offering.  ... remains a challenge in management. With nearly ... the seven major markets of the world ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... LLC, a premier developer of innovative quality control products ... (PET) imaging, is pleased to announce the only ... of Standards and Technology (NIST) for accurate measurement of ... 1 millicurie (37 MBq) strength.  Fluorine-18 is an important ...
... Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following ... Monday, February 28, 2011 at 4:30 p.m. ET / 1:30 ... log onto our Web site listed above. If you are ... the webcast will be available for a limited time at ...
... NEW YORK and SAN DIEGO, Feb. 14, 2011 Polaris ... today announced the enrollment of the first patient in a ... of small cell lung cancer (SCLC).  The trial, sponsored by ... Duke University Medical Center and will soon commence at St. ...
Cached Biology Technology:RadQual, LLC Announces a New Industry Leading Dose Calibrator Reference Standard 2Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer 2Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer 3
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... New article postings for Geology cover glacial erosion ... changing the face of Earth; collisional shortening in the ... typhoon Morakot in 2009; a new type of iron ... using fossil marine plankton records in 70-million-year-old sediments as ...
... chemical sensors for your iPhone, and new materials with ... power, and new crime scene investigation techniques this month ... materials, interfaces, and processing. Detailed press releases will follow ... & Exhibition will take place Oct. 27 - Nov. ...
... Michael J. Fox Foundation for Parkinson,s Research and Shake ... project by Sydney,s Garvan Institute of Medical Research to ... Parkinson,s disease. Long non-coding RNAs are complex molecules, ... regulatory roles in the body. Unlike conventional genes, they ...
Cached Biology News:Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 2Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 3Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 4Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 5Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 6Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 7Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 8Glacial buzz-saws, gold in fool's gold, fingerprints in sea water, and fluvial iron 9AVS science symposium in Long Beach Oct. 27 -- Nov. 2 2Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2
... paraffin tissue array is designed for ... interest in extensive panels of different ... heart, kidney, liver, lung, muscle, spleen ... positively charged glass slide. Each ...
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
LIVE/DEAD® Sperm Viability Kit *200-1000 assays*...
in vitro Translation, Accessory Products...
Biology Products: